Develops cancer drugs using nanoencapsulation.
Jun 2026Revenue $324M/yrExpenses $446M/yr
No trendCash runway ≈ 2.5 years from Jun 2026
Figures by year
When will Fulgent Genetics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $324M and expenses $446M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $323M | $414M | −$91.1M |
| Dec 2024 | $283M | $357M | −$73.9M |
| Dec 2023 | $289M | $485M | −$196M |
| Dec 2022 | $619M | $440M | $179M |
| Dec 2021 | $993M | $317M | $676M |
| Dec 2020 | $422M | $132M | $290M |
| Dec 2019 | $32.5M | $33.0M | −$428K |
| Dec 2018 | $21.4M | $26.4M | −$5.07M |
| Dec 2017 | $18.7M | $22.2M | −$3.48M |
| Dec 2016 | $18.3M | $17.4M | $918K |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.